James Nagarajah on [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study
10:02
Ali Landman on the European Congress of Radiology 2026
14:07
Kayleigh Bhangdia on breast cancer GBD study 2023
17:30
Dylan Graetz and Erica Kaye on qualitative research in oncology
42:06
Jesse Plascak and Marissa Baker on cancer mortality rates by occupation among US workers
22:54
Andre Pfob and Peter Dubsky on The Lucerne Toolbox 3
25:41
Gary Rodin on The human crisis in cancer: a Lancet Oncology Commission
10:46
Matthias Preusser on the phase 2 TUXEDO-3 trial
17:10
Andrea Necchi on TAR-200 plus cetrelimab as neoadjuvant therapy in patients with muscle-invasive bladder cancer
12:15
Linda Bi, Ruchit Patel, Chloe Gui, Farshad Nassiri, and Matija Snuderl on TERT expression and TERT promoter mutations in meningiomas
14:22
Jinming Li on patterns in genomic mutations among patients with early-onset colorectal cancer
7:36
Abdalla Awidi on cancer control in the Middle East
8:22
ASCO 2025 Debrief
14:45
Caroline Robert on treatments for patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN trial)
10:45
Richard Bryant on transperineal vs transrectal biopsy for prostate cancer
18:02
Professor Amar U. Kishan on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA)
7:33
Ariana Znaor on cancer surveillance in the Eastern Mediterranean region
20:03
Ian Tannock on Common Sense Oncology principles for phase 3 randomised clinical trials
18:03
Yannick Romero on the changing landscape of national cancer control plans
24:40
M Saiful Huq and Mostafa Aziz Sumon on the series Cancer Care in South Asian Association for Regional Cooperation (SAARC) Countries
22:15
Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma
15:07
Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination
17:21
May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics
40:45
Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02)
13:22
Emmy Boerrigter on dose selection of novel anticancer drugs
11:41